Literature DB >> 30302199

Propylene glycol-free melphalan as conditioning regimen for autologous transplantation in myeloma.

Omar S Aljitawi1,1, Parameswaran Hari2,2.   

Abstract

High-dose melphalan has been the drug of choice for preparative regimens for autologous stem cell transplantation in multiple myeloma. Propylene-free melphalan (Evomela™) is a newer formulation of melphalan, which incorporates Captisol® to produce a stable product upon reconstitution. In addition to avoiding propylene glycol with its' potential side effects, this approach improves the overall stability of reconstituted melphalan and can ensure intended dose delivery. In this paper, we review the published literature regarding this formulation. We focus on its' chemistry, pharmacokinetics and clinically available data for its use in myeloma autologous stem cell transplantation setting.

Entities:  

Keywords:  high-dose chemotherapy; melphalan; multiple myeloma; propylene glycol-free melphalan

Year:  2016        PMID： 30302199      PMCID： PMC6171969          DOI： 10.2217/ijh-2015-0006

Source DB:  PubMed          Journal:  Int J Hematol Oncol        ISSN： 2045-1393


  10 in total

1.  Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.

Authors:  Philippe Moreau; Thierry Facon; Michel Attal; Cyrille Hulin; Mauricette Michallet; Frédéric Maloisel; Jean-Jacques Sotto; François Guilhot; Gérald Marit; Chantal Doyen; Jérôme Jaubert; Jean-Gabriel Fuzibet; Sylvie François; Lotfi Benboubker; Matthieu Monconduit; Laurent Voillat; Margaret Macro; Christian Berthou; Véronique Dorvaux; Bernard Pignon; Bernard Rio; Thomas Matthes; Philippe Casassus; Denis Caillot; Norbert Najman; Bernard Grosbois; Régis Bataille; Jean-Luc Harousseau
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

Authors:  Michele Cavo; S Vincent Rajkumar; Antonio Palumbo; Philippe Moreau; Robert Orlowski; Joan Bladé; Orhan Sezer; Heinz Ludwig; Meletios A Dimopoulos; Michel Attal; Pieter Sonneveld; Mario Boccadoro; Kenneth C Anderson; Paul G Richardson; William Bensinger; Hans E Johnsen; Nicolaus Kroeger; Gösta Gahrton; P Leif Bergsagel; David H Vesole; Hermann Einsele; Sundar Jagannath; Ruben Niesvizky; Brian G M Durie; Jesus San Miguel; Sagar Lonial
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

3.  Preclinical comparison of intravenous melphalan pharmacokinetics administered in formulations containing either (SBE)7 m-β-cyclodextrin or a co-solvent system.

Authors:  Maria Koltun; Julia Morizzi; Kasiram Katneni; Susan A Charman; David M Shackleford; Michelle P McIntosh
Journal:  Biopharm Drug Dispos       Date:  2010-11       Impact factor: 1.627

4.  Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study.

Authors:  Kevin C Wilson; Christine Reardon; Arthur C Theodore; Harrison W Farber
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

5.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Authors:  J Anthony Child; Gareth J Morgan; Faith E Davies; Roger G Owen; Susan E Bell; Kim Hawkins; Julia Brown; Mark T Drayson; Peter J Selby
Journal:  N Engl J Med       Date:  2003-05-08       Impact factor: 91.245

6.  A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.

Authors:  Parameswaran Hari; Omar S Aljitawi; Carlos Arce-Lara; Rajneesh Nath; Natalie Callander; Gajanan Bhat; Lee F Allen; Keith Stockerl-Goldstein
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-29       Impact factor: 5.742

Review 7.  Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.

Authors:  S Vincent Rajkumar; Francis Buadi
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020

Review 8.  Recognition, treatment, and prevention of propylene glycol toxicity.

Authors:  Tausif Zar; Charles Graeber; Mark A Perazella
Journal:  Semin Dial       Date:  2007 May-Jun       Impact factor: 3.455

9.  Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation.

Authors:  O S Aljitawi; S Ganguly; S H Abhyankar; M Ferree; R Marks; J D Pipkin; J P McGuirk
Journal:  Bone Marrow Transplant       Date:  2014-06-09       Impact factor: 5.483

10.  Propylene glycol-associated renal toxicity from lorazepam infusion.

Authors:  Ndidi E Yaucher; Jeffrey T Fish; Heidi W Smith; Jeffrey A Wells
Journal:  Pharmacotherapy       Date:  2003-09       Impact factor: 4.705
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.